CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $62,729 | -19.1% | 1,382 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $77,586 | +24.1% | 1,382 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $62,508 | +11.3% | 1,382 | 0.0% | 0.00% | +33.3% |
| Q4 2022 | $56,178 | -39.6% | 1,382 | -2.9% | 0.00% | -50.0% |
| Q3 2022 | $93,000 | +6.9% | 1,424 | -1.0% | 0.01% | +20.0% |
| Q2 2022 | $87,000 | -3.3% | 1,439 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $90,000 | -17.4% | 1,439 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $109,000 | -32.3% | 1,439 | 0.0% | 0.01% | -44.4% |
| Q3 2021 | $161,000 | -30.9% | 1,439 | 0.0% | 0.01% | -25.0% |
| Q2 2021 | $233,000 | +67.6% | 1,439 | +26.3% | 0.01% | +50.0% |
| Q1 2021 | $139,000 | -12.0% | 1,139 | +10.3% | 0.01% | -20.0% |
| Q4 2020 | $158,000 | +83.7% | 1,033 | 0.0% | 0.01% | +66.7% |
| Q3 2020 | $86,000 | +11.7% | 1,033 | -1.9% | 0.01% | 0.0% |
| Q2 2020 | $77,000 | +92.5% | 1,053 | +13.0% | 0.01% | +50.0% |
| Q1 2020 | $40,000 | – | 932 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |